ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial
Titel:
ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial
Auteur:
Giavina-Bianchi, Pedro Cua, Eric Risso, Karine Mondain, Véronique Vissian, Anaïs Joie, Cécile Pouletty, Philippe Gineste, Paul Ehrlich, Hartmut J. Kalil, Jorge